These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20409441)

  • 21. Implementation and analysis of a multifaceted intervention for alcohol use disorder from a single academic urban emergency department.
    Duvalyan E; Falade I; Fan W; Foe M; Mvemba A; Zussman JW; Geier C; LeSaint KT; Graglia S
    Acad Emerg Med; 2024 May; 31(5):456-462. PubMed ID: 38380769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Availability of addiction medications in private health plans.
    Horgan CM; Reif S; Hodgkin D; Garnick DW; Merrick EL
    J Subst Abuse Treat; 2008 Mar; 34(2):147-56. PubMed ID: 17499959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.
    Knudsen HK; Ducharme LJ; Roman PM
    Drug Alcohol Depend; 2007 Mar; 87(2-3):164-74. PubMed ID: 16971059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The state of pharmacotherapy for the treatment of alcohol dependence.
    Garbutt JC
    J Subst Abuse Treat; 2009 Jan; 36(1):S15-23; quiz S24-5. PubMed ID: 19062347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.
    Savage SA; Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
    J Subst Abuse Treat; 2012 Jan; 42(1):16-24. PubMed ID: 21831565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment.
    Knudsen HK; Ducharme LJ; Roman PM
    J Health Soc Behav; 2007 Jun; 48(2):195-210. PubMed ID: 17583274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.
    Abraham AJ; Knudsen HK; Rieckmann T; Roman PM
    J Stud Alcohol Drugs; 2013 Mar; 74(2):258-65. PubMed ID: 23384373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of state policies in the adoption of naltrexone for substance abuse treatment.
    Heinrich CJ; Hill CJ
    Health Serv Res; 2008 Jun; 43(3):951-70. PubMed ID: 18454775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence.
    Harris AH; Oliva E; Bowe T; Humphreys KN; Kivlahan DR; Trafton JA
    Psychiatr Serv; 2012 Jul; 63(7):679-85. PubMed ID: 22549276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knowledge and attitudes about pharmacotherapy for alcoholism: a survey of counselors and administrators in community-based addiction treatment centres.
    Thomas SE; Miller PM
    Alcohol Alcohol; 2007; 42(2):113-8. PubMed ID: 17172258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoption and implementation of new technologies in substance abuse treatment.
    Roman PM; Johnson JA
    J Subst Abuse Treat; 2002 Jun; 22(4):211-8. PubMed ID: 12072165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.
    Knudsen HK; Ducharme LJ; Roman PM
    J Subst Abuse Treat; 2006 Jun; 30(4):363-73. PubMed ID: 16716852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Access to Addiction Pharmacotherapy in Private Health Plans.
    Reif S; Horgan CM; Hodgkin D; Matteucci AM; Creedon TB; Stewart MT
    J Subst Abuse Treat; 2016 Jul; 66():23-9. PubMed ID: 27211993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates of prescription orders for United States active duty service members diagnosed with alcohol use disorder.
    Peters ZJ; Kincaid MW; Greenberg JG; Quah RF; Curry JC
    Subst Abus; 2021; 42(4):638-645. PubMed ID: 32870103
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study.
    Marienfeld C; Iheanacho T; Issa M; Rosenheck RA
    Addict Behav; 2014 Feb; 39(2):434-8. PubMed ID: 23790742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
    Wiercigroch D; Sheikh H; Hulme J
    Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):4. PubMed ID: 31931831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between medication adherence and treatment outcomes: the COMBINE study.
    Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
    Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
    Helton SG; Lohoff FW
    Psychiatry Res; 2015 Dec; 230(2):121-9. PubMed ID: 26455758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention.
    Dermody SS; Wardell JD; Stoner SA; Hendershot CS
    Ann Behav Med; 2018 Aug; 52(9):787-797. PubMed ID: 30124761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.